Invesco Biotechnology & Genome ETFPBE
PBE
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1.09% more ownership
Funds ownership: 34.64% [Q3] → 35.73% (+1.09%) [Q4]
5% less capital invested
Capital invested by funds: $92.4M [Q3] → $88.2M (-$4.2M) [Q4]
6% less funds holding
Funds holding: 102 [Q3] → 96 (-6) [Q4]
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
39% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 31
Research analyst outlook
We haven’t received any recent analyst ratings for PBE.
Financial journalist opinion
Neutral
Seeking Alpha
2 weeks ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Neutral
Zacks Investment Research
1 month ago
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.
Neutral
Zacks Investment Research
1 month ago
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.
Neutral
Zacks Investment Research
3 months ago
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.
Neutral
Zacks Investment Research
4 months ago
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
The Invesco Biotechnology & Genome ETF (PBE) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Neutral
Zacks Investment Research
5 months ago
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.
Neutral
Zacks Investment Research
6 months ago
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.
Neutral
Zacks Investment Research
7 months ago
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund launched on 06/23/2005.
Neutral
Zacks Investment Research
8 months ago
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
The Invesco Biotechnology & Genome ETF (PBE) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Neutral
Zacks Investment Research
10 months ago
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund launched on 06/23/2005.
Charts implemented using Lightweight Charts™